Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$798M |
| 2 |
Netflix
NFLX
|
+$608M |
| 3 |
UnitedHealth
UNH
|
+$517M |
| 4 |
Apple
AAPL
|
+$461M |
| 5 |
GE Vernova
GEV
|
+$296M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$527M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$372M |
| 3 |
Meta Platforms (Facebook)
META
|
+$362M |
| 4 |
Advanced Micro Devices
AMD
|
+$328M |
| 5 |
Palantir
PLTR
|
+$327M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Healthcare | 15.79% |
| 3 | Consumer Discretionary | 12.36% |
| 4 | Financials | 11.53% |
| 5 | Industrials | 8.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
DDI
3051
DoubleDown Interactive
DDI
$676M
| $291K | ﹤0.01% |
30,400
-16,400
| -35% | -$161K |
2023 Q4
6 quarters
|
|
3052
Manchester United
MANU
$3.54B
| $291K | ﹤0.01% |
16,327
+5,611
| +52% | +$83.1K |
2025 Q1
1 quarter
|
|
3053
IZEA Worldwide
IZEA
$40.1M
| $290K | ﹤0.01% |
113,703
+35,300
| +45% | +$83.7K |
2021 Q2
16 quarters
|
|
3054
Destination XL Group
DXLG
$21.8M
| $290K | ﹤0.01% |
261,100
-7,600
| -3% | -$8.32K |
2022 Q3
11 quarters
|
|
3055
Deutsche Bank
DB
$63.3B
| $289K | ﹤0.01% |
9,762
-2,960
| -23% | -$78.2K |
2025 Q1
1 quarter
|
|
|
ESPR
3056
DELISTED
Esperion Therapeutics
ESPR
| $288K | ﹤0.01% |
+292,400
| New | +$293K |
2025 Q2
0 quarters
|
|
3057
Data Storage Corp
DTST
$7.81M
| $287K | ﹤0.01% |
83,800
+1,900
| +2% | +$6.87K |
2023 Q2
8 quarters
|
|
3058
Spruce Power Holding Corp
SPRU
$30M
| $286K | ﹤0.01% |
141,820
+3,000
| +2% | +$5.86K |
2021 Q4
14 quarters
|
|
3059
Lantern Pharma
LTRN
$12.1M
| $286K | ﹤0.01% |
90,600
+1,800
| +2% | +$6.08K |
2022 Q1
13 quarters
|
|
3060
Acumen Pharmaceuticals
ABOS
$155M
| $286K | ﹤0.01% |
246,588
-10,112
| -4% | -$10.9K |
2024 Q2
4 quarters
|
|
3061
Karyopharm Therapeutics
KPTI
$13.7M
| $284K | ﹤0.01% |
65,814
+4,600
| +8% | +$22.6K |
2021 Q2
16 quarters
|
|
3062
First Trust Capital Strength ETF
FTCS
$7.54B
| $282K | ﹤0.01% |
+3,100
| New | +$276K |
2025 Q2
0 quarters
|
|
3063
Hain Celestial
HAIN
$50.4M
| $282K | ﹤0.01% |
185,222
+157,900
| +578% | +$369K |
2024 Q3
3 quarters
|
|
3064
Farmers & Merchants Bancorp
FMAO
$476M
| $280K | ﹤0.01% |
+11,081
| New | +$266K |
2025 Q2
0 quarters
|
|
3065
Lucid Diagnostics
LUCD
$122M
| $280K | ﹤0.01% |
243,279
-215,786
| -47% | -$279K |
2025 Q1
1 quarter
|
|
3066
Bogota Financial
BSBK
$116M
| $279K | ﹤0.01% |
35,774
-2,077
| -5% | -$14.9K |
2021 Q1
17 quarters
|
|
3067
Bit Digital
BTBT
$465M
| $278K | ﹤0.01% |
+126,972
| New | +$280K |
2025 Q2
0 quarters
|
|
3068
Educational Development Corp
EDUC
$11.1M
| $276K | ﹤0.01% |
205,945
-8,900
| -4% | -$11.5K |
2018 Q1
29 quarters
|
|
|
AXIA.PR
3069
DELISTED
AXIA Energia American Depositary Shares Preferred Class B1
AXIA.PR
| $275K | ﹤0.01% |
42,053
+4,422
| +12% | +$28.6K |
2024 Q3
3 quarters
|
|
3070
Catalyst Bancorp
CLST
$67.8M
| $275K | ﹤0.01% |
22,200
-700
| -3% | -$8.22K |
2024 Q3
3 quarters
|
|
3071
Hydrofarm Holdings
HYFM
$4.05M
| $274K | ﹤0.01% |
73,363
-1,100
| -1% | -$3.45K |
2021 Q4
14 quarters
|
|
3072
Vita Coco
COCO
$3.38B
| $274K | ﹤0.01% |
7,600
-39,200
| -84% | -$1.31M |
2024 Q4
2 quarters
|
|
3073
Daxor
DXR
$60.8M
| $274K | ﹤0.01% |
28,021
-100
| -0.4% | -$811 |
2013 Q2
48 quarters
|
|
3074
Optical Cable Corp
OCC
$140M
| $274K | ﹤0.01% |
94,223
-1,980
| -2% | -$5.69K |
2013 Q2
48 quarters
|
|
|
VXRT
3075
DELISTED
Vaxart
VXRT
| $270K | ﹤0.01% |
+597,443
| New | +$260K |
2025 Q2
0 quarters
|
|
Similar funds
Renaissance Technologies's Q2 2025 Portfolio in Review
As of Q2 2025, Renaissance Technologies held 4,018 positions worth $75.2B, up 14% from $66.1B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Renaissance Technologies's Q2 2025 filing shows 612 new, 1,577 increased, 1,314 reduced and 496 closed positions. Its largest new stake was UnitedHealth: 1,352,129 shares worth $422M. The largest sale was Broadcom, an estimated $527M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 17% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Renaissance Technologies's largest Q2 2025 buy was UnitedHealth: 1,352,129 shares worth $422M.
- Renaissance Technologies added most to NVIDIA in Q2 2025, an estimated $798M increase.
- Renaissance Technologies's biggest Q2 2025 reduction was Broadcom, cutting an estimated $527M.
- Renaissance Technologies fully exited Advanced Micro Devices in Q2 2025, selling an estimated $328M.
- Renaissance Technologies's ten largest holdings make up 12% of its $75.2B portfolio in Q2 2025.
- Renaissance Technologies opened 612 new positions and closed 496 in Q2 2025.
- Renaissance Technologies's portfolio value rose 14% quarter-over-quarter to $75.2B.
Based on Renaissance Technologies's 13F filing for Q2 2025, filed 13 Aug 2025.